SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is a top trending stock as investors analyze its J.P. Morgan Healthcare Conference presentation for critical updates on its oral VK2735 program and commercialization plans, reinforced by a recent Chief Commercial Officer hire and the completion of its obesity maintenance study enrollment. The community is sharply divided between bullish expectations for a significant partnership or buyout, driven by the drug's perceived 'best-in-class' potential, and concerns over stock price suppression and management's strategy within the highly competitive metabolic market.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid discussions surrounding potential new tariffs on countries trading with Iran and a reported DOJ probe into Fed Chair Powell, sparking debate on market stability and the independence of the central bank. Despite these headlines, a strong bullish sentiment prevails among many, emphasizing buying opportunities during dips and highlighting the market's resilience. The community is actively discussing whether the market can sustain its upward momentum given these geopolitical and regulatory concerns, often with frustration from those anticipating a significant pullback.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending due to strategic announcements around its ambitious "Meta Compute" AI infrastructure buildout, which includes securing multi-gigawatt nuclear energy agreements to power future data centers. This aggressive AI push, alongside reported layoffs in the Reality Labs division, is sparking mixed community reactions regarding the scale of investment versus potential returns. Investors are keenly observing these developments as Meta intensifies its position in the global AI race, with many awaiting further clarity on the long-term vision.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Travere Therapeutics is trending sharply lower following the FDA's request for additional clarification on the clinical benefit of FILSPARI for FSGS, a development that has caused significant market jitters ahead of its PDUFA decision. While many in the community are concerned this signals a potential Complete Response Letter, a notable counter-narrative suggests the sell-off is an overreaction, pointing to the company's strong commercial execution for FILSPARI in IgAN and solid financial standing as reasons to buy the dip.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as the U.S. recommendation to add Duchenne Muscular Dystrophy to the newborn screening panel significantly broadens the long-term market for its Elevidys gene therapy. While recent preliminary financial updates led to stock volatility, the community is actively discussing perceived undervaluation and the substantial pipeline potential, particularly in light of expanding early patient identification.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is trending amid intense community debate, fueled by its ongoing underperformance and deep frustration with current management's ability to deliver sustained profitability. However, many investors remain bullish, highlighting the company's position as a global leader in virtual care and its potential to capture a significant share of the rapidly expanding AI healthcare market. Recent partnerships, such as with TytoCare for at-home diagnostics, and anticipation around the $50 billion Rural Health Transformation Program are seen as key catalysts, driving speculation of a significant long-term rebound for the stock.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is actively trending amid high community anticipation for potential major news, particularly concerning its GaN and SiC power solutions for next-generation AI data centers and a possible collaboration with NVIDIA. Investors are keenly discussing its substantial short interest, fueling speculation of a significant short squeeze alongside bullish technical setups.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is actively trending following a significant agreement with Meta Platforms to develop 1.2 gigawatts of nuclear energy for its AI data centers, with its CEO also set to appear on CNBC. While bulls view this as a crucial validation for advanced nuclear technology and a catalyst for future partnerships, skeptics point to the company's lack of revenue, unapproved designs, and notable insider selling against a distant commercial timeline. The market remains divided on whether the growing demand for AI power justifies Oklo's current valuation, especially as the community awaits overdue plutonium awards.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo is trending amid a recent CFO transition and its reaffirmed commitment to prioritizing user growth and product innovation, despite strong preliminary Q4 metrics. The stock's significant decline has sparked a heated debate, with bulls viewing it as an oversold opportunity supported by strong fundamentals and AI integration, while bears argue the business model is vulnerable to free AI alternatives and cite ongoing chart weakness.

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

BDSX is trending due to strong preliminary Q4 and full-year 2025 results, which reported significant revenue growth and reaffirmed guidance for Adjusted EBITDA positivity. The community is actively discussing the stock's explosive volume and price action, with many speculating on continued momentum and a potential short squeeze. However, some investors express caution, pointing to the company's cash position and potential future dilution within the volatile biotech sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wedbush Boosts Huron Consulting Group (NASDAQ:HURN) Price Target to $200.00

Wedbush upped their price objective on shares of Huron Consulting Group from $165.00 to $200.00 and gave the stock an "outperform" rating in a research report on Monday...

Robeco Institutional Asset Management B.V. Sells 28,656 Shares of Huron Consulting Group Inc. $HURN

Robeco Institutional Asset Management B.V. reduced its holdings in shares of Huron Consulting Group Inc. (NASDAQ:HURN - Free Report) by 67.6% during the 3rd quarter, according to the company in its...

Huron Consulting Group (NASDAQ:HURN) Sets New 12-Month High - Here's What Happened

Huron Consulting Group (NASDAQ:HURN) Reaches New 1-Year High - Here's What Happened...

Ekta Singh-Bushell Sells 126 Shares of Huron Consulting Group (NASDAQ:HURN) Stock

Huron Consulting Group Inc. (NASDAQ:HURN - Get Free Report) Director Ekta Singh-Bushell sold 126 shares of the stock in a transaction dated Monday, January 5th. The stock was sold at an average price...

Huron Consulting Group (NASDAQ:HURN) Given New $207.00 Price Target at Barrington Research

Barrington Research increased their target price on shares of Huron Consulting Group from $190.00 to $207.00 and gave the stock an "outperform" rating in a research note on Monday...

Ninety One UK Ltd Invests $8.33 Million in Huron Consulting Group Inc. $HURN

Ninety One UK Ltd acquired a new position in shares of Huron Consulting Group Inc. (NASDAQ:HURN - Free Report) in the third quarter, according to the company in its most recent disclosure with the...

Burney Co. Takes $938,000 Position in Huron Consulting Group Inc. $HURN

Burney Co. acquired a new stake in Huron Consulting Group Inc. (NASDAQ:HURN - Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 6,393...

Rice Hall James & Associates LLC Has $2.76 Million Holdings in Huron Consulting Group Inc. $HURN

Rice Hall James & Associates LLC decreased its holdings in Huron Consulting Group Inc. (NASDAQ:HURN - Free Report) by 31.9% during the 3rd quarter, according to the company in its most recent...

Benchmark Raises Huron Consulting Group (NASDAQ:HURN) Price Target to $215.00

Benchmark lifted their price objective on shares of Huron Consulting Group from $180.00 to $215.00 and gave the company a "buy" rating in a research note on Wednesday...

Is Charles River Associates (CRAI) Stock Outpacing Its Business Services Peers This Year?

Here is how CRA International (CRAI) and Huron Consulting (HURN) have performed compared to their sector so far this year.

Huron Consulting Group, Inc. engages in the provision of technology, data, and analytics solutions. It operates through the following segments: Healthcare, Education, and Commercial. The Healthcare segment focuses on serving acute care providers including national and regional health systems, academic health systems, and community health systems, and public, children, and critical access hospitals, and non-acute care providers including physician practices and medical groups, payors, and long-term care or post-acute providers. The Education segment is involved in public and private colleges and universities, research institutes, and other education-related organizations. The Commercial segment includes industries outside of healthcare and education including financial services and energy and utilities. The company was founded in 2002 and is headquartered in Chicago, IL.

Huron Consulting Group Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

HURN
Huron Consulting Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest HURN News

HURNHuron Consulting Group Inc